473 W 12th Ave
Columbus, OH 43210
Phone: (614) 293-4967
Associate Professor-Clinical, Cardiovascular Medicine
Physician, FGP-Cardiovascular Medicine
I have mentored the heart failure fellows during their training including career opportunities after completing training. I have also met with potential candidates in general cardiology to help them decide about subspecialty training in heart failure or other programs.
I have met with multiple student and residents to discuss their interests in Internal Medicine, Cardiology, and/or Heart Failure training, also writing letters of recommendation for residency and fellowship applications.
Since I applied for promotion in 2010, I have published 14 peer reviewed manuscripts, 2 editor reviewed manuscripts and 3 book chapters (with an additional chapter in press currently). One chapter is in a well known cardiology textbook, Hursts: The Heart on diagnosis/management of HF, for which I wrote the device based therapy section for the 12th edition and then updated it for the 13th ed. I have been involved in various research projects including the Parachute device, which is a ventricular partitioning device in anterior MI/HF. I was a coauthor on the published feasibility results in 2011 and we are currently enrolling in the pivotal trial.
Invasive hemodynamic monitoring in HF has been a major focus. I have worked with various devices for assessing HF filling pressures, including RV, LA and PA pressures. I was the primary investigator at OSU for the Cardiomems device, starting with implanting all 3 patients in the feasibility study in 2006 and all 18 enrolled in the Champion trial. I also had a primary role in post-implant management of pressures for treatment vs control patients. It was FDA approved in May 2014 and I implanted the first sensor in the US after FDA approval. I was part of the publication on use of the cardiomems in HFpEF and the early safety trial. In addition, I have given lectures on hemodynamic monitoring with this device at the AAHFN conferenceand in Zurich.This is the first invasive hemodynamic monitoring device to be approved for managing chronic HF patients in the ambulatory setting.
Another research project involves phrenic nerve stimulation in the treatment of central sleep apnea in HF. I implanted a temporary lead to stimulate the phrenic nerve in the feasibility study patients, and am now the OSU PI on the pivotal trial. We have presented multiple abstracts (6 total), and I was coauthor on the published manuscript on this treatment.
Given my initial training with ICD, CRT (cardiac resynchronication therapy or biventricular pacing) implants, I started a CRT non-responder clinic in which I use echo to adjust pacer programming of atrial-ventricular (AV) and left/right ventricular (VV) pacing delays to improve cardiac output. I developed the protocol for echo optimization and also gained medical center approval for this to be recognized as an official privilege in echo reading (limited Doppler for echo optimization). I also worked on a protocol with one of my colleagues to use a non-invasive approach with lung Doppler signal to optimize CRT (ongoing). Also, we were the top enrolling site for EchoCRT, which evaluated CRT in narrow QRS patients to try to expand indications. I was the OSU PI on this trial and gave a lecture at the European investigator’s meeting in Rome on how to perform echo optimization for the study protocol.
Currently, we have minimal guidelines regarding driving for VAD patients. Our research project on driving risks for VAD patients was an oral presentation at the 2013 ISHLT (International Society for Heart and Lung Transplantation) and was a highlighted study in their newsletter from that meeting. I also coauthored an abstract and manuscript on a research project reviewing the impact of insurance and socioeconomic status on outcomes for our VAD patients.I have served as section editor for Current Heart Failure Reports, the Nonpharmacologic Therapy section since 2011 (5 published volumes through 2015 and currently working on 2016). Each year, I have to select 6-7 topics in this field, choose authors, and edit the manuscripts. We have expanded the invitations to international authors to improve readership. In addition to writing a chapter, I was also the HF section editor for the Specialty Board Review: Cardiology, 1st ed, 2012, which involved editing 9 chapters.
I have participated in two website publications - one article for Heart Insight Magazine sponsored by the AHA in which I answered questions about heart transplantation and the second for Web MD as the heart failure physician interviewed in May 2016 for an article on ways patients can help with their treatment.
I started as Internal Medicine faculty at OSU in the heart failure section of cardiology in July 2006 after completing cardiology training at West Virginia University and advanced heart failure/transplant fellowship at OSU. Initially, I performed device implants in the electrophysiology lab based on training at OSU for both heart failure (HF) and defibrillator/biventricular pacing implants. After 3 years, I focused on our heart failure program and did not perform EP procedures after 2009. In 2010, I became the medical director of the cardiac transplant program and the director of the advanced HF/transplant fellowship program. In October 2011, I was promoted to associate professor of clinical Internal Medicine.
Since I applied for promotion to associate professor in 2010, I have published 14 peer-reviewed manuscripts, 3 book chapters, and 2 editor reviewed manuscripts. One chapter is in a well-known cardiology textbook, Hursts: The Heart on diagnosis/management of HF, for which I wrote the device based therapy section for the 12th and 13th editions. Most of my research projects have focused on device therapy in heart failure. I have been coauthor on publications including the Parachute device (a ventricular partitioning device in anterior MI/HF), hemodynamic monitoring with the Cardiomems device, and phrenic nerve stimulation in the treatment of central sleep apnea in HF. Invasive hemodynamic monitoring in HF has been a major focus. I was the primary investigator at OSU for all three of studies on the Cardiomems device, starting with implanting all 3 patients in the feasibility study in 2006 and all 18 enrolled in the Champion trial. I also had a primary role in post-implant management based on pulmonary artery pressures for treatment vs control patients. It was FDA approved in May 2014; I implanted the first sensor in the US after FDA approval in June 2014. In addition to co-authoring publications on the use of Cardiomems in HFpEF and the early safety trial, I have given lectures on hemodynamic monitoring with this device at the AAHFN (American Association of HF Nurses) annual conference, Mount Nittany Medical Center, and at the University Hospital Zurich. This is the first invasive hemodynamic monitoring device to be approved for managing chronic HF patients in the ambulatory setting, and OSU has been nationally recognized for our role with this device in HF management.
My research activity at OSU includes serving as principal investigator on 23 trials since starting as faculty with funding totaling $1.4 million from industry sponsored trials. I have also been involved in more than 30 additional trials as a co-investigator during my career at OSU, most of which involve participating in follow-up research visits for HF assessment and clinical management. We we were the top enrolling site for EchoCRT, which evaluated CRT in narrow QRS patients to try to expand indications. I was the PI at OSU on this trial and gave a lecture at the European investigator’s meeting in Rome on how to perform echo optimization for the study protocol.
Given my initial training with ICD and CRT implants, I started a CRT non-responder clinic in which I use echo to adjust pacer programming of AV, VV delays to improve cardiac output in patients who have not benefitted clinically or by echo after biventricular pacing in HF. I developed the protocol for echo optimization, and also gained medical center approval for this to be recognized as an official privilege in echo reading (limited Doppler for echo optimization). Most of my referrals are from HF or electrophysiology colleagues at OSU, but I am the only HF faculty who performs this study. From my CRT and heart failure experience, I have served on adverse events adjudication committees for three device trials, invited by Medtronic for the PROMPT trial (CRT after MI), REVERSE post-approval study (CRT in mild HF) and the PSR Sure Scan Post Approval Study, which consist of only 2-3 heart failure cardiologists.
As the medical director of the cardiac transplant program since 2009, I have worked with our team to improve volume & outcomes in the recent years. Our annual volume was 10-14 transplants per year during 2010-13 (CMS requirement is minimum of 10 per year). Through overhauling our program in the past few years, we reached 19 annual transplants in 2014 and 25 in 2015 - while improving our one year survival. Prior to 2014, our program exceeded 20 annual transplants only twice since starting in 1986. For the current calendar year 2016, we have transplanted 10 patients in 5 months (as of 5/19/16). Our program had below average one year transplant survival per the SRTR national rates and “flagged” in July 2012 (80.7% vs expected 92.4%). We have met national rates since instituting major protocol changes in 2012-13. Last SRTR releases: our 1 yr survival was 92.2% vs 90.4% expected (June 2015) and 88.8 vs 91.2% (Dec 2015). To achieve these measures, we revamped all aspects of our program including pre-transplant approach, post-management and immunosuppression. I was a principal contributor to the decision making and implementation plan for these program changes (summarized in the Quality Narrative). The most beneficial additions have been multidisciplinary rounds with CT surgery/HF cardiology/all involved in care of inpatient VAD and transplant patients at 1 pm daily and weekly outpatient “virtual rounds” in which transplant cardiologists review patients seen in clinic that week along with biopsies, labs, & management. This weekly review has reduced patient complications and improved outcomes as evidenced above with SRTR data. An example of recognition for our improvement is that our heart transplant program is now a Center of Excellence with Optum insurance through their Clinical Sciences Institute; Optum recognizes certain national programs for clinical excellence and identifies those that best exemplify the highest quality based on evidence-based medicine. Our heart transplant program first received this recognition in June 2015 and maintained the recognition for 2016, which is based upon on our quality outcomes and solid volume in the past few years. Cleveland Clinic is the only other heart transplant program in Ohio with this status (representing only two of four Ohio adult heart transplant programs with this designation as of April 2016). Our heart transplant program was also recognized at this year's 2016 Professional Symposium for the Ohio Solid Organ Transplant Consortium (OSOTC) consisting of the 6 Ohio transplant programs; I was invited to serve as the only heart transplant representative on two panel discussions of challenges solid organ programs face with listing high acuity patients and dual organ candidates. Other panelists were from lung and liver transplant programs from Cleveland Clinic, University of Cincinnati, University Hospitals Case and Nationwide Children's Hospitals. Our improvement in volume has also been recognized nationally as I was invited to UVA’s annual cardiovascular conference in Feb 2016 to discuss how to grow a VAD and transplant program, and later invited to Penn State to discuss the same topic for the advanced heart failure program at Hershey Medical Center in August 2016.
We do not have a medical director of the ventricular assist device (VAD) program; as the heart transplant director, I essentially take on a leadership role with the VAD program. I am the primary HF cardiologist participating in our annual JCAHO accreditation reviews, which requires several meetings to review our outcomes and performance measures, education of all staff involved in patient care, documentation, etc. I worked with our surgeons to change the post-VAD management from surgical f/u to a weekly clinic staffed by HF cardiology to improve HF management and identify those who are appropriate transplant candidates rather than remaining destination therapy. I also helped develop our patient selection criteria and anticoagulation protocol, and participate in our monthly quality meetings and projects to review performance improvement. Our annual volume in 2010-13 was 31-39 for long-term VADs and improved to 52 in 2014 and 48 in 2015. Our one year survival is 79% vs 80% in the INTERMACS database (our national metric), which is averaged from >150 hospitals implanting VADs.
My major accomplishment as the HF fellowship director has been in obtaining ACGME accreditation in 2013, which was the first year any US HF program could be approved. I completed and submitted the application in 2012 which included developing policies, competency assessments, and updating our curriculum for advanced HF training. We have since completed our first site visit with the ACGME in early May 2016 (final report pending). I developed a HF specific lecture series for our fellow(s) geared towards the HF boards since their didactic education had primarily been included with the general cardiology fellows’ lectures when given by our subspecialty faculty. I expanded the HF fellow curriculum to include our VAD and transplant quality meetings, HF research meetings, journal club, and Heart Care Council for the transplant program; the goal is to increase their exposure to clinical trial management, quality improvement projects and how to interpret quality data in order to make protocol changes.
I have served as section editor for Current Heart Failure Reports, the Nonpharmacologic Therapy section since 2011 (an invited annual position); each year, I select 6-7 topics in this field, choose authors, and edit the manuscripts. Since 2015, I have been an editorial board member for the Journal of Cardiac Failure, which is the official journal of the Heart Failure Society of America; membership is by invitation for US and international heart failure cardiologists.
I am co-chair of our Heart Failure Operations Council. We meet monthly and have been tasked with reducing HF admissions and length of stay. We are trying to streamline our discharge medication process as we have noted multiple errors; the pilot project, n=21, showed a 30d readmission rate of 14% (vs 32% in Ross for CY2015).
I have been recognized on the Best Doctors List 2010, 2013-2015; based on patient satisfaction scores at OSU, I have received the Certificate of Excellence for Outstanding Achievement in Patient Service in 2010, 2014 and 2015. I have served on the UNOS Region 10 Heart Review Board for the past 6 years and review UNOS 1A listings/extensions and exception criteria within the region (Ohio, Indiana, Michigan). Members include leaders in heart transplant from the Cleveland Clinic and Michigan programs (total of 7 regional centers with a representative on the board). When there is a concern with 1A/1AE listing or extending a high status listing, we have conference calls to discuss the individual cases. I am also the OSU heart transplant representative for the Ohio Solid Organ Transplantation Consortium, which involves reviewing and approving all patients listed at any of the 6 adult/children heart transplant programs in Ohio.
|2015||Akiko Mano, Ohio State University College of Medicine. Graduated 0.|
|2016||Umair Ahmad, The Ohio State University. Graduated 0.|
|2009 - 2010||Donald Kikta, Ohio State University College of Medicine. Graduated 2010.|
|2010 - 2011||Angela Brittsan, Ohio State University College of Medicine. Graduated 2011.|
|2011 - 2012||Mangeet Chahal, Ohio State University College of Medicine. Graduated 2012.|
|2012 - 2013||Sitaramesh Emani, Ohio State University College of Medicine. Graduated 2013.|
|2012 - 2013||Gina Mentzer, Ohio State University College of Medicine. Graduated 2013.|
|2012 - 2014||Sakima Smith, Ohio State University College of Medicine. Graduated 2014.|
|2013 - 2014||Adam Pleister, Ohio State University College of Medicine. Graduated 2014.|
|2014 - 2015||Khadijah Breathett, Ohio State University College of Medicine. Graduated 2015.|
|2002 - present||Medical Licensure: West Virginia Board of Medicine|
|2005 - present||Board Certification: American Board of Internal Medicine|
|2005 - present||Medical Licensure: State Medical Board of Ohio|
|2010 - present||Board Certification: American Board of Internal Medicine|
|2015 - present||Board Recertification: American Board of Internal Medicine|
|2002 - 2012||Board Certification: American Board of Internal Medicine|
Diagnosis and Management of Heart Failure
Overview of Clinical Trials on Resynchronization and Combined ICD-Resynchronization in Heart Failure
Diagnosis and Management of Heart Failure
Heart Failure in Women
Devices for Heart Failure
|07/01/2006||Advanced Heart Failure Outpatient Clinic (Ross Heart Hospital)|
|07/01/2006||Heart Transplant Outpatient Clinic (Ross Heart Hospital)|
|07/01/2011||Ventricular Assist Device Outpatient Clinic (Ross Heart Hospital)|
Pacemaker and implantable cardioverter-defibrillator implantation in patients chronically anticoagulated: continuation of warfarin versus bridging with heparin
The Ohio State University medical center experience with adult extra corporeal membrane oxygenation (ECMO) for cardiogenic shock
Late Bleeding and Thrombotic Complications with Continuous Flow Ventricular Assist Devices
Rabbit Antithymocyte Globulin Dosing and Complications in Heart Transplant Induction and Rejection
Off Pump Placement of Implantable LVADs Results in Significant Reductions of Transfusion Requirements and Re-Exploration for Hemorrhage
Results of Chronic Phrenic Nerve Stimulation using the RespiCardia(TM) System are Comparable to Acute Results in the Improvement of Central Sleep Apnea: First in Man Experience
Percutaneous Left Ventricular Partitioning for Ischemic Heart Failure: Results of the US-PARACHUTE Feasibility Study
Comparison of Right and Left Unilateral Phrenic Nerve Stimulation in the Termination of Central Apnea Events
A NOVEL APPROACH USING PHRENIC NERVE STIMULATION TO TREAT CENTRAL SLEEP APNEA: FIRST-IN-MAN EXPERIENCE
Results from the Freedom Trial: Assess the safety and efficacy of frequent optimization of cardiac resynchronization therapy
Trends in Body Mass Index Following Long Term Mechanical Circulatory Support
Upgrading to resynchronization therapy after chronic right ventricular pacing improves left ventricular remodelling.
Characteristics of Patients Receiving Ventricular Assist Devices as a Bridge to Cardiac Transplant Candidacy
Central sleep apnea events are terminated by phrenic nerve stimulation
Initial performance data of a defibrillation lead utilizing the draft IS4 connection system
Bridge to Candidacy: A Fulfilled Promise?
Single Night Transvenous Phrenic Nerve Stimulation Improves Central Sleep Apnoea In Systolic Heart Failure
Strong Tranthyretin (Prealbumin) Immunostaining in Cardiac Amyloid Deposits, a Potential Pitfall for Surgical Pathologists
Consideration for Serial Surveillance of Aortic Valve Following Implantation of Continuous Flow Left Ventricular Assist Device
Driver's Education: A Single Center Experience on the Incidence and Safety of Driving with LVADS
Integrating Palliative Care in the Management of Patients Considered for Mechanical Circulatory Support
Phrenic Nerve Stimulation Improves Circulatory Delay in Patients With Heart Failure and Central Sleep Apnea
Heart Transplant Recipients with LVADs and Pulmonary Hypertension Do Not Benefit from 'Oversized' Donor Hearts
Echocardiographic derived LVEF enhances the risk stratification of the CHADS-Vasc score in heart failure patients with atrial fibrillation
Atrial Fibrillation is Associated With Worse Outcomes in Patients With Diastolic Heart Failure than Patients With Systolic Heart Failure
The CHADS-Vasc Score Has Better Predictive Value Than CHADS2 for Heart Failure Patients with Atrial Fibrillation
Hit the Road: A Multicenter Evaluation of Driving with LVADs
Elderly Heart Transplant Recipient Long-Term Survival Is Not Dependent on Donor Age: A Conditional Survival Analysis
Changes in Thoracic Impedance Measured via the Azygos Vein with the remede (R) System Indicate Worsening Heart Failure
Ischemic Cardiomyopathy Patients on Coumadin for Atrial Fibrillation Experience More Adverse Events with Clopidogrel or Percutaneous Coronary Intervention
Has the Survival in Heart Transplant Recipients Older > 65years Improved Over the Decades?
Cost Comparison between Heart Transplantation and Left Ventricular Assist Device Implantation
Heart Transplant Recipient and Donor Age Mismatching: Should the Older Recipient Be Paired with the Older Donor?
Is There a Need for Patient Specific Informed Consent in Heart Transplantation?
Syncope and Junctional Escape Arrhythmia as a Presentation of Delayed Mixed High Grade Cellular and Antibody Mediated Rejection Eight Years Post Orthotopic Heart Transplant
Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents
Is Education the Key to Success? Association of Formal Education and Outcomes in Left Ventricular Assist Devices
Indium-111 Nuclear-Labeled Leukocyte Imaging in Mechanical Circulatory Support Infections
From Clinical Research to Clinical Practice: Development of a Comprehensive Workflow for the Cardiomems™ Heart Failure System
|1995||B.A., West Virginia University|
|1999||M.D., West Virginia University|
|2002||None Indicated, Robert C. Byrd Health Sciences Center of West Virginia University|
|2005||None Indicated, Robert C. Byrd Health Sciences Center of West Virginia University|
|2006||None Indicated, The Ohio State University|
|2008||European Journal of Heart Failure|
|2008||Pacing and Clinical Electrophysiology, reviewed submission in January 2008 and resubmission in March 2008|
|2009||European Heart Journal|
|2009||Journal of the American Society of Echocardiography|
|2009 - 2012||Speciality Board Review: Cardiology|
|2010 - present||Section Editor 2013 (Vol 10), Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise in Current Heart Failure Reports, pub 3/2013|
|2010 - present||Section Editor 2012 (Vol 9), Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise in Current Heart Failure Reports, pub 3/2012|
|2010 - present||Section Editor 2011 (Vol 8), Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise in Current Heart Failure Reports, pub 3/2011|
|2010 - present||Section Editor 2016 (Vol 13), Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise in Current Heart Failure Reports|
|2010 - present||Section Editor 2015 (Vol 12), Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise in Current Heart Failure Reports, pub 2/2015|
|2010 - present||Section Editor 2014 (Vol 11), Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise in Current Heart Failure Reports, pub 3/2014|
|2010||European Heart Journal|
|2010||European Heart Journal|
|2010||Reviewed abstracts submitted to Heart Failure Society of America's 14th Annual Scientific Sessions, Abstract category: Surgery, transplantation, devices. April 2010|
|2010||Journal of the American Society of Echocardiography|
|2010||Journal of the American Society of Echocardiography|
|2010||Case Reports in Medicine|
|2011||European Heart Journal|
|2011||New England Journal of Medicine|
|2011||The American Journal of the Medical Sciences|
|2011||Pacing and Clinical Electrophysiology|
|2013||Journal of Cardiac Failure|
|2013||Genetic Mutation CNI in pediatric transplant patients, Grant for OSOTC|
|2014||Journal of Cardiac Failure|
|2014||Circulation Heart Failure|
|2014||Smart Homecare Technology and TeleHealth|
|2015 - present||Journal of Cardiac Failure|
|2016||Circulation: Heart Failure|
|2016||Circulation: Heart Failure|
|2005 - present||Leadership in Cardiology Award. during fellowship training.|
|2010 - present||Best Doctors List. Best Doctors, Inc.|
|2010 - present||Certificate of Excellence in recognition of Outstanding Achievement in Patient Service. Based upon patient satisfaction survey scores.|
|2013||Best Doctors List. Best Doctors, Inc.|
|2014 - present||Certificate of Excellence in recognition of Outstanding Achievement in Patient Service. Based upon patient satisfaction survey scores.|
|2014 - present||Best Doctors List. Best Doctors, Inc.|
|2015 - present||Certificate of Excellence in recognition of Outstanding Achievement in Patient Service. Based upon patient satisfaction survey scores.|
|2015 - present||Best Doctors List. Best Doctors, Inc.|
|June 2010||Hasan A."Updating Heart and Vascular website regarding cardiovascular topics"|
|October 2012||Hasan, A. Brochure: Heart transplant patient experience."The Power of One: Grateful Patient Stories from the OSU Wexner Medical Center"|
|April 2014||Hasan A."Advanced Heart Failure, Transplant, and Ventricular Assist Device Program at OSU Heart & Vascular Center Mailer" WriterGirl & Associates|
|November 2015||Emani S, Hasan A."Heart Transplant Q & A" Heart Insight Magazine, sponsored by AHA|
|May 2016||Hasan, A."Web MD: Ways patients with advanced heart failure can play a role in their treatment" Web MD|
Optimizing pacing delays in cardiac resynchronization therapy
Diastolic Heart Failure: Managing the Other half of Heart Failure
Chronic Heart Failure: Pathophysiology and Overview of Cardiac Resynchronization Therapy
Atrial-Ventricular (AV) Delay Optimization Training
Maximizing Patient Benefit from Cardiac Resynchronization Therapy
Cardiac Resynchronization Therapy in Chronic Heart Failure: Optimizing Biventricular Pacing after Implantation
Updates on Management of Chronic Heart Failure
Heart Failure: What is it? How do you treat it? How is it prevented?
Coronary Artery Disease and Heart Failure
Atrial-Ventricular (AV) Delay Optimization Training
Update in Management of Chronic Heart Failure
The Heart Failure Program at OSU: Update on Clinical Trials and Transplant
Treatment of Heart Failure in Women: Are We Doing Enough?
Implantable Hemodynamic Monitoring in Chronic Heart Failure
Gender Differences in the Treatment of Heart Failure
54 y/o, Remote MI, on Maximal Medical Therapy and LVEF 20%, LVEDD 7.5 cm and Symptomatic HF: CRT vs. Transplant, Heart Failure Viewpoint
62 y/o With Chronic Systolic HF and Recent Decrease in Exercise Tolerance: BNP or Clinical Evaluation or Both?
The Responder: Imaging Profile
QRS Morphology and Duration
Controversies in Cardiac Resynchronization Therapy: Mild Heart Failure
Know Your Ejection Fraction
Heart Failure in Women: Advances in Treatment and Therapeutic Options
Hemodynamics and the Role of Pressure-Guided Therapy in Heart Failure Management: Champion Trial Overview
Acute Decompensated Heart Failure: Evidence Based Guidelines
Chronic Left Ventricular Assist Device in Advanced Heart Failure: How Do We Decide When to Explant - Case Presentation
Chronic LVAD Therapy in Advanced Heart Failure: When to Refer and What are the Outcomes?
End-Stage Heart Failure: Left Ventricular Assist Devices and Cardiac Transplant in Women
Living with Heart Failure
Evaluation, Diagnosis and Treatment of Cardiomyopathies
Growing a Ventricular Assist Device and Transplant Program
Growing a Ventricular Assist Device and Transplant Program
Risks and Challenges of Dual Organ Transplantation
High Acuity Transplantation: Management and Improved Decision Making
|present||First ACGME site visit for heart failure/transplant fellowship program since initial accreditation in 2013. Ohio State University Medical Center.|
|present||based on my participation in all Cardiomems trials (Champion).|
|present||Transplant protocol major changes based on quality data, outcomes, consultant recommendations.|
|present||Obtained ACGME approval for initial accreditation for Advanced Heart Failure & Cardiac Transplant Program to start 7/1/2013. Ohio State University Medical Center.|
|2008 - present||Unverferth Family House Board.|
|2009 - present||Presentation: Update on Heart Transplant Program from 6/09 (Outcomes, Volume, Goals). To Comprehensive Transplant Center Executive Committee. Columbus, OH.|
|2009 - present||Presentation on Current Status of Heart Transplant Program: strategies to increase volume. To Medical Center Executive Committee. Columbus, OH.|
|2009 - present||Presented update on OSU Transplant Program for site visit by Blue Distinction Centers for Transplant (BDCT). sponsored by BlueCross and BlueShield Association.|
|2010 - present||Started Cardiac Resynchronization Therapy Nonresponder Clinic and developed Echo Optimization Protocol used by our echocardiography lab for CRT optimization.|
|2010 - present||Developed Patient Selection Protocol for Longterm Ventricular Assist Devices.|
|2012 - present||Revised heart transplant protocol regarding steroid taper.|
|2012 - present||Product Surveillance Registry REVERSE Post-Approval Study – CEC, Clinical Events Adjudication Committee. Sponsored by Medtronic.|
|2013 - present||Mentor.|
|2013 - present||Transplant protocol updates: Developed algorithm to expedite process for new inpatient and outpatient referrals.|
|2016 - present||Product Surveillance Registry Sure Scan Post-Approval Study, Clinical Events Committee. Sponsored by Medtronic.|
|- 2009||Consultant for Cardiomems, Inc. FDA Meeting to discuss Humanitarian Exemption for use of Cardiomems Sensor for Invasive Hemodynamic Monitoring in Patients with Mechanical Circulatory Support Devices. Cardiomems.|
|2009||Revised and updated heart transplant protocol for OSUMC.|
|2007 - 2010||FREEDOM Clinical Trial Steering Committee. Sponsored by St. Jude Medical.|
|2010||Developed Heart-Kidney transplant protocol with transplant nephrology.|
|2011 - 2015||PRomPT Clinical Trial – AEAC, Adverse Events Adjudication Committee. Sponsored by Medtronic.|
|2012 - 2016||Chair Data Safety Monitoring Board. Clinical Trial: Early Treatment with Aldosterone Antagonism Attenuates Cardiomyopathy in.|
Optimization of cardiac resynchronization therapy